Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 26,082 | 14,417 | 13,794 | 10,891 | 10,533 |
| Cost of Goods | 12,079 | 9,199 | 11,166 | 9,880 | 10,877 |
| Gross Profit | 14,003 | 5,218 | 2,628 | 1,011 | -344 |
| Operating Expenses | 112,436 | 105,960 | 99,134 | 100,821 | 100,083 |
| Operating Income | -98,354 | -100,543 | -96,340 | -98,930 | -99,550 |
| Other Income | 2,679 | 2,480 | 4,188 | 1,872 | 6,533 |
| Pre-tax Income | -95,675 | -98,063 | -92,152 | -97,058 | -93,017 |
| Income Tax | 167 | -523 | -779 | N/A | N/A |
| Net Income Continuous | -95,842 | -97,540 | -91,373 | -92,996 | -93,017 |
| Net Income | $-95,842 | $-97,540 | $-91,373 | $-92,996 | $-93,017 |
| EPS Basic Total Ops | -0.34 | -0.40 | -0.39 | -0.43 | -0.43 |
| EPS Basic Continuous Ops | -0.34 | -0.40 | -0.39 | -0.42 | -0.43 |
| EPS Diluted Total Ops | -0.34 | -0.40 | -0.39 | -0.43 | -0.43 |
| EPS Diluted Continuous Ops | -0.34 | -0.40 | -0.39 | -0.42 | -0.43 |
| EPS Diluted Before Non-Recurring Items | -0.34 | -0.40 | -0.39 | N/A | N/A |
| EBITDA(a) | $-91,156 | $-91,575 | $-88,963 | $-91,377 | $-91,972 |